两种含顺铂联合化疗方案治疗晚期非小细胞肺癌的临床效果  

Clinical Efficacy of Chemotherapy including Cisplatin for Advanced Non-small Cell Lung Cancer

作　　者：龚卫华 浦旭红 冯国光 

机构地区：[1]上海市崇明县第二人民医院,202157 [2]上海交通大学医学院附属新华医院崇明分院外科,202150

出　　处：《实用癌症杂志》2014年第6期722-723,共2页The Practical Journal of Cancer

摘　　要：目的探究顺铂分别联合紫杉醇与吉西他滨治疗晚期非小细胞肺癌的临床疗效及不良反应。方法收集214例确诊为晚期非小细胞肺癌的患者资料,并依据治疗方案进行分组:TP组(紫杉醇+顺铂)和GP组(吉西他滨+顺铂),回顾性分析2组患者的临床特点、病理分型、分期、临床疗效及不良反应,并利用统计学软件分析。结果 TP组治疗有效率为38.3%;GP组治疗有效率为36.2%,2组临床疗效无明显差异(P>0.05);2组的不良反应主要表现在血液毒性方面,差异较明显。结论紫杉醇联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效无显著性差异,均可作为临床抗癌一线化疗药物,可根据患者耐受及不良反应等适当选择联合用药。Objective To explore the clinical efficacy and side effects of paclitaxel and gemcitabine plus cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer. Methods 214 cases of advanced non-small cell lung cancer patients were divided into TP group( paclitaxel + cisplatin) and GP group( gemcitabine + cisplatin). The clinical features,pathology typing,staging,clinical efficacy,and adverse reactions of the 2 groups were retrospectively analyzed by statistics software.Results The effective rate of TP group was 38. 3%; and the effective rate of GP group was 36. 2%,there had no obvious difference( P > 0. 05); adverse reactions of the 2 groups was mainly manifested in the blood toxicity,the difference between the 2groups was obvious. Conclusion Paclitaxel and gemcitabine plus cisplatin in treatment of advanced non-small cell lung cancer had no significant difference,it can be used as the first-line anticancer chemotherapy drug in clinical. Appropriate combination treatment should be chosen according to the patient's tolerance and adverse reactions.

关 键 词：晚期非小细胞肺癌 顺铂 化疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]